SNDX Syndax Pharmaceuticals, Inc

NASDAQ
$18.20

Syndax Pharmaceuticals, Inc (SNDX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal Bearish Selling ran elevated versus SNDX's own trailing one-year pace, with 93% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
3
5 transactions
Purchases
$0
0 shares
Sales
$2.1M
105,914 shares
Net activity
-$2.1M
purchases less sales

How much of that selling was preplanned? 93% planned / 7% discretionary

10b5-1 plan sales $2.0M 3 transactions · 97,890 shares
Discretionary sales $152.4K 2 transactions · 8,024 shares

Largest single sale: $784.8K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Metzger Michael A Chief Executive Officer Sell 10b5-1 32,375 $24.24 $784.8K 484,843 −6.3% of holding
Botwood Nicholas A.J. Head of R&D, CMO Sell 10b5-1 31,235 $18.14 $566.6K 60,885 −33.9% of holding
Botwood Nicholas A.J. Head of R&D, CMO Sell 10b5-1 34,280 $18.00 $617.0K 60,885 −36% of holding
Metzger Michael A Chief Executive Officer Sell 6,847 $18.99 $130.0K 484,843 −1.4% of holding
Goldan Keith A. Chief Financial Officer Sell 1,177 $18.99 $22.4K 139,252 −0.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.